Although uncoupling the contribution of each glycan in complex molecules such as antibodies is challenging, our study points to significantly enhanced affinity and effector functions of glycomodified antibodies targeting HER2+ and FRα+ breast cancers. Here, ERBB2 is linked to breast carcinoma.